Navidea Biopharmaceuticals, Inc. (NAVB)

NAVB Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018
Revenue	0.07	0.53	0.92	0.03	0.32
Revenue Growth (YoY)	-87.65%	-41.91%	3337.57%	-91.75%	-82.19%
Cost of Revenue	0.18	0	0	0.01	0.1
Gross Profit	-0.12	0.53	0.91	0.02	0.23
Selling, General & Admin	7.96	7.45	6.69	6.28	7.7
Research & Development	5.97	5.14	4.93	5.34	4.22
Other Operating Expenses	-0.03	-0.01	-0.02	-0.63	0
Operating Expenses	13.93	12.59	11.63	10.98	11.07
Operating Income	-14.05	-12.06	-10.71	-10.96	-10.85
Interest Income	0.33	0.01	0.01	0.03	0
Interest Expense	1.1	0.01	0	0.03	0.03
Other Expense / Income	0.35	-0.35	0.02	-0.02	5.25
Pretax Income	-15.18	-11.71	-10.72	-10.94	-16.17
Income Tax	2.04	0.02	-0.08	0	0
Net Income	-17.22	-11.73	-10.64	-10.95	-16.13
Shares Outstanding (Basic)	29	29	24	14	9
Shares Outstanding (Diluted)	29	29	24	14	9
Shares Change	-	22.80%	66.02%	68.80%	2.72%
EPS (Basic)	-0.59	-0.40	-0.45	-0.76	-1.89
EPS (Diluted)	-0.59	-0.40	-0.45	-0.76	-1.89
Free Cash Flow	-9.38	-10.55	-8.59	-9.41	4.23
Free Cash Flow Per Share	-0.32	-0.36	-0.36	-0.65	0.50
Gross Margin	-181.71%	100.00%	99.89%	74.95%	70.04%
Operating Margin	-21402.08%	-2269.07%	-1170.60%	-41184.60%	-3363.29%
Profit Margin	-26221.65%	-2207.08%	-1162.82%	-41120.85%	-5000.12%
Free Cash Flow Margin	-14282.76%	-1984.44%	-938.53%	-35357.39%	1311.31%
EBITDA	-14.05	-12.43	-10.71	-10.96	-5.56
EBITDA Margin	-21402.08%	-2337.93%	-1170.60%	-41184.60%	-1722.58%
Depreciation & Amortization	0.1	0.08	0.07	0.14	0.15
EBIT	-14.15	-12.5	-10.78	-11.11	-5.71
EBIT Margin	-21548.03%	-2352.41%	-1178.30%	-41727.51%	-1769.21%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.